Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid

Clinical Oral Investigations

Volumn 17, Issue 4, 2013, Pages 1259-1266

  Mozzati, Marco ^a   Martinasso, Germana ^a   Maggiora, Marina ^a   Scoletta, Matteo ^a   Zambelli, Marta ^a   Carossa, Stefano ^a   Oraldi, Manuela ^a   Muzio, Giuliana ^a   Canuto, Rosa Angela ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bisphosphonates; Cytokines; HMGR; Jaw; Osteonecrosis; RANKL OPG

Indexed keywords

EID: 84876430864     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-012-0800-7     Document Type: Article

References (33)

1. Pazianas M (2011) Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 103: 232-240.
2. Mehrotra B (2009) Bisphosphonates-role in cancer therapies. J Oral Maxillofac Surg 67: 19-26.
3. Dunford JE, Kwaasi AA, Rogers MJ et al (2008) Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 51: 2187-2195.
4. Marcus R, Feldman D, Nelson D et al (2008) Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Nelson D, Rosen C (eds) Osteoporosis, 3rd edn. Elsevier, Burlington, pp 1725-1742.
5. Frei M, Bornstein MM, Schaller B et al (2010) Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case. J Oral Maxillofac Surg 68: 863-867.
6. Treister NS, Sook-Bin W (2009) Bisphosphonate-associated osteonecrosis of the jaws. In: Rosen CJ, Compston JE, Lian JB (eds) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. Wiley, Hoboken, pp 505-509.
7. Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients, and by "in vitro" research. Clin Cancer Res 9: 2893-2897.
8. Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544.
9. Hansen T, Kunkel M, Weber A et al (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
10. Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63: 682-689.
11. Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44: 4-10.
12. Ohe JY, Kwon YD, Lee HW (2012) Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clin Oral Investig 16: 1153-1159.
13. Koch FP, Merkel C, Ziebart T et al (2012) Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig 16: 79-86.
14. Mozzati M, Gallesio G, Arata V et al (2012) Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol 48: 469-474.
15. Mozzati M, Martinasso G, Cocero N et al (2011) Influence of superpulsed laser therapy on healing processes following tooth extraction. Photomed Laser Surg 29: 565-571.
16. Bianchi SD, Scoletta M, Cassione FB et al (2007) Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104: 249-258.
17. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3: CD003474.
18. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420-432.
19. La Verde N, Bareggi C, Garassino M et al (2008) Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution. Support Care Cancer 16: 1311-1315.
20. Ruggiero S, Gralow J, Marx RE et al (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2: 7-14.
21. Vandone AM, Donadio M, Mozzati M et al (2011) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23: 193-200.
22. Lo JC, O'Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68: 243-253.
23. Shannon J, Shannon J, Modelevsky S et al (2011) Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 340: c246. doi: 10. 1111/j. 1532-5415. 2011. 03713. x.
24. Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Oteoporos Int 9: S66-S80.
25. Santini D, Vincenzi B, Caraglia M et al (2007) A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Ann Oncol 18: 201-202.
26. Rufo A, Del Fattore A, Capulli M et al (2011) Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res 26: 1891-1903. doi: 10. 1002/jbmr. 410.
27. Jimi E, Furuta H, Matsuo K et al (2010) The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis 17: 462-468. doi: 10. 1111/j. 1601-0825. 2010. 01781. x.
28. Hewitt RE, Lissina A, Green AE et al (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101-111.
29. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761.
30. Kraus D, Deschner J, Jäger A et al (2012) Human β-defensins differently affect proliferation, differentiation, and mineralization of osteoblast-like MG63 cells. J Cell Physiol 227: 994-1003. doi: 10. 1002/jcp. 22808.
31. Krishnan V, Shuman LA, Sosnoski DM et al (2011) Dynamic interaction between breast cancer cells and osteoblastic tissue: comparison of two- and three-dimensional cultures. J Cell Physiol 226: 2150-2158.
32. Landesberg R, Woo V, Cremers S et al (2011) Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 1218: 62-79. doi: 10. 1111/j. 1749-6632. 2010. 05835. x.
33. Rustemeyer J, Bremerich A (2010) Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig 14: 59-64.